Replies to post #516629 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

SkyLimit2022,

This trial will determine if DCVax-L given early enough after surgery is enough on it’s own with Poly ICLC vs with the combo. That’s a huge question mark for valuation and this makes it a fair comparison because chemo/rad is out of the picture. Bottom line is it’s ALL on the line. The only other question is whether or not unmethylated will benefit from earlier treatment or the combo as up to 50% might be cured from L plus Poly ICLC alone. “Go big or go home”!; ). Best wishes.

[HyGro]

We'll see how FDA responds to the manipulated DCVax-L trial.

[biosectinvestor]

I would not argue the US Government invented DCVax. It was patented and created before that, but grants are always a big part of the learning once a product has been invented and certainly many, many institutions have studied and published generally about the science of dendritic cells and of course that research is critical to the accumulation of learning that leads to all discoveries around immunotherapies.

But shareholders paid mostly for the trial for DCVax, the combination trial, which is to explore questions around the pathology of treating the disease and the use of multiple immunotherapy drugs that were already developed is critical to the next stage, but it’s not about invention of DCVax. The NIH and UCLA are in the combination patent though. So that is a kind of invention. They are finding the understanding of how these combinations work, at least this first study. I expect NWBO will do many studies in the future with various combinations. At least that is what I hope. It would be great if the NIH partially funded some of that work.

But if you check the history of the various patents for the original DCVax variations, those are owned completely by NWBO.